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Purpose: Neointimal hyperplasia (NIH) is complete by 3 weeks in rabbit vein grafts implanted into the arterial circulation.
Activation of the mitogen-activated protein kinase (MAPK) family of protein kinases is thought to be critical in
remodeling events such as cellular proliferation, differentiation, and migration, as found in NIH. We previously
demonstrated that antisense basic fibroblast growth factor (ASbFGF) inhibited the synthesis of basic fibroblast growth
factor (bFGF) in the balloon injury model of NIH. We examined the effect of ASbFGF on NIH and the time course of
MAPK, extracellular signal-regulated kinase (ERK) 1/2, c-Jun N-terminal protein kinase (JNK), and p38 kinase
activation in arterialized vein grafts.
Methods: Carotid interposition of a vein bypass graft was performed in 75 New Zealand White rabbits. Segments of the
external jugular vein were transfected with a replication-deficient adenovirus containing the messenger RNA sequence for
rat ASbFGF at 1  1010 plaque-forming units per milliliter; control animals were given phosphate-buffered saline
solution (PBS) alone. Rabbits were killed at 30 minutes, 4 days, 7 days, and 21 days (n  8). Four grafts in each group
were fixed with formalin and embedded in paraffin, then processed with elastin-collagen and hematoxylin-eosin stains.
The other four grafts were individually frozen, and total protein was extracted. Phosphorylation of MAPK, ERK1/2,
JNK, and p38, was determined with Western blot analysis and immunohistochemistry. Groups were compared with
analysis of variance.
Results: The thickness of neointima in the PBS group and the ASbFGF group at 21 days was 60.2  2.1 and 39.4  2.1
m, respectively (P < .01). In both the control and ASbFGF groups, all 3 MAPKs demonstrated activation compared
with preimplantation levels. However, when compared with the PBS group the ASbFGF group showed greater than 33%
inhibition of all three MAPKs by day 4 and day 7 (P < .05), but no significant difference in any MAPK activation by day
21 (P > .05, all groups). Cells staining positive for activated MAPK were found in the neointima and adventitia of vein
grafts in both the PBS and ASbFGF groups.
Conclusion: MAPKs are activated during the first week after vein graft implantation. Grafts treated with ASbFGF
demonstrated reduced MAPK activation and less neointimal thickening. These results suggest that the process of vein
graft adaptation to the arterial circulation, and subsequent NIH, may depend on basic fibroblast growth factor activity,
which is mediated, at least in part, by a MAPK-dependent mechanism. (J Vasc Surg 2003;37:866-73.)
Neointimal hyperplasia (NIH) is a common response
after vein graft implantation, leading to graft stenosis and
occlusion.1-3 The incidence of thrombosis and occlusion in
coronary and lower extremity bypass grafts is reported to be
as high as 20% at 1 year.4-7
Tissue remodeling in NIH is mediated by many growth
factors and cytokines, eg, basic fibroblast growth factor
(bFGF), platelet-derived growth factor, interleukin–1,
transforming growth factor, and tumor necrosis factor–
.8,9 bFGF is a member of the heparin-binding mitogens,
characterized by their affinity for heparin and ability to
stimulate both endothelial and smooth muscle cell prolif-
eration.7,10-13 Rapid and dramatic NIH is complete by 3
weeks in rabbit vein grafts implanted into the arterial circu-
lation.1,14-17 Sterpetti et al9 reported increases in bFGF at 7
days and 4 weeks in these grafts, and these increases corre-
lated with NIH. We previously demonstrated that in bal-
loon-injured carotid arteries antisense bFGF (ASbFGF)
inhibited synthesis of bFGF, with peak effect at day 4, and
inhibition of NIH in a dose-dependent fashion, supporting
a role for bFGF in the development of NIH.18
The precise signal transduction pathways that link vas-
cular injury or vein graft adaptation to development of NIH
are not completely defined. The mitogen-activated protein
kinase (MAPK) superfamily is composed of ubiquitous
intracellular serine and threonine kinases that are thought
to be important in transducing signals from the cytoplasm
to the nucleus that are required for cell proliferation, dif-
ferentiation, and migration. MAPKs include extracellular
signal-regulated kinase (ERK), c-Jun N-terminal protein
kinase (JNK), and p38 kinase (p38).19
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Our purpose was to determine whether bFGF has a role
in the development of NIH in the rabbit vein graft model
and whether the MAPK pathway is a mechanism of bFGF
action.
METHODS
Generation of recombinant adenoviruses
The recombinant adenoviral vector encoding ASbFGF
(Ad.ASbFGF) and the recombinant adenoviral vector en-
coding bacterial -galactosidase (Ad.LacZ) were generated
as described previously.18,20-22 In brief, Ad.ASbFGF was
constructed by replacement of -galactosidase comple-
mentary DNA with a 1.1 kilobase pair (kbp) of rat bFGF
cDNA that contained the entire coding sequence in reverse
orientation in the plasmid Ad.CMV LacZ shuttle vector,
followed by homologous recombination with the E1,E3–
deleted human adenovirous serotype 5 mutant dl7001 in
human embryonal kidney 293 cells (American Type Cul-
ture Collection, Bethesda, Md).18,21-24 Ad.LacZ was used
as the control viral vector in these experiments. Phosphate-
buffered saline (PBS) served as a second control. RNA
produced by Ad.ASbFGF is an effective block of bFGF
protein synthesis, as demonstrated in smooth muscle cell
culture.21
Rabbit model of interposition vein graft and in vivo
gene transfer
Seventy-five adult male New Zealand white rabbits
(3.0  0.2 kg) were anesthetized with an intramuscular
injection of ketamine (50 mg/kg; Aveco Co, Fort Dodge,
Iowa), xylazine (5 mg/kg; Mobay Corp, Shawnee, Kan),
and acepromazine (1 mg/kg; Aveco Co). Neither mechan-
ical ventilation nor supplemental intravenous fluid admin-
istration was required.
Common carotid artery vein grafts were performed
according to previously published reports.1,20 In brief, a
2.5 cm segment of the external jugular vein, lacking valves,
was isolated by ligation of the proximal and distal vein. A
small venotomy was made in the distal vein. After irrigation
with PBS, a 300 L volume of either adenoviral vector (at
1  1010 plaque-forming units [PFU] per milliliter) in
PBS, Ad.LacZ control vector, or PBS alone was injected
into the lumen of the isolated vein and maintained at 120
mm Hg pressure for 30 minutes.18,20
After systemic heparinization (1000 U; Elkins-Sinn
Inc, Cherry Hill, NJ), the carotid artery was dissected and
clamped. A segment of carotid artery equal to the original
in situ length of the vein segment was excised. The vein
segment, free of surrounding tissues, was grafted with
end-to-end anastomoses with 9-0 nylon continuous run-
ning suture (Sharpoint Surgical Specialties Corp, Reading,
Pa). Arterial blood flow was restored to the carotid artery
and vein graft. The neck incision was closed in two layers,
and the animals were placed under a warming light until
fully recovered from anesthesia. After recovery, the rabbits
were maintained on a light-dark (12-12 hour) cycle at
24° C and fed a normal diet and water as desired. Animal
care complied with the Principles of Laboratory Animal
Care formulated by the National Society of Medical Re-
search and the Guide for the Care and Use of Laboratory
Animals (National Institutes of Health Publ No 86-23, rev
1985).
Tissue preparation
Formalin fixation. Forty-one arterialized vein grafts
(AVGs) were examined with Western blot analysis, and 34
were examined with histologic analysis. Grafts were har-
vested at 30 minutes, 4 days, 7 days, and 21 days, using the
formalin perfusion fixation technique. Normal jugular veins
were also harvested as controls. At these time points, the
vessels were perfusion fixed in situ at a perfusion pressure of
100 to 110 mm Hg. Normal saline solution was instilled
first, followed by 10% formalin solution, through a large-
bore cannula placed retrograde in the thoracic aorta. The
carotid arteries that contained the interposition vein grafts
were harvested en bloc for further immersion fixation. The
samples were separated into three parts evenly and embed-
ded in paraffin, then processed with hematoxylin-eosin
stain.
Protein isolation for Western blot analysis. Four
animals from the Ad.LacZ, ASbFGF, and PBS groups in
each time course were killed, and the vein grafts were
harvested as above but without formalin fixation, then
snap-frozen in liquid nitrogen. Samples were homoge-
nized, and the protein was isolated with lysis buffer con-
taining 50 mmol/L of HEPES (N-2-hydroxyethylpipera-
zine-N-2-ethanesulfonic acid) buffer; pH, 7.4), 150
mmol/L of sodium chloride, 10% glycerol, 1% Triton
X-100, 1.5 mmol/L of magnesium chloride, 1 mmol/L of
sodium pyrophosphate, 1 mmol/L of sodium orthovana-
date, 10 g/mL of leupeptin, 10 g/mL of aprotinin, and
1 mmol/L of phenylmethylsulfonylfluoride. Cell extracts
were centrifuged at 15,000g for 10 minutes. The protein
concentration of solubilized cell lysates was measured by
the Bradford method.
Documentation of gene transfer to AVG tissue
X-gal chromagen staining. Vein graft specimens
were stained with X-gal chromagen to detect the presence
of -galactosidase activity, to indicate successful Ad.lacZ
infection, according to the method we previously pub-
lished.20
RT-PCR for ASbFGF. Confirmation of successful
vein graft infection by the Ad.ASbFGF vector was docu-
mented with reverse transcriptase polymerase chain reac-
tion according to the method we previously described.20,22
Measurements of neointima thickness
Neointima thickness was determined from the middle
portion of each graft in three separate sections. Computer-
ized digital morphometry with Scion Image 1.62c software
(Scion Corp, Frederic, Md) was used to assess neointimal
thickness at eight equidistant sampling points around the
circumference of the graft in cross section. The neointima
was defined as the layer from the lumen to the internal
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elastic lamina. The measurements were obtained in blinded
fashion.
Western blot analysis
Laemmli sample buffer was added to equivalent protein
amounts of each sample, followed by boiling for 5 minutes.
Samples were resolved with 10% sodium dodecylsulfate–
polyacrylamide gel electrophoresis and transferred to nitro-
cellulose membrane. The blots were incubated in 5% nonfat
dry milk with bFGF, phospho-specific MAPK, or total
MAPK antibodies. Anti-bFGF monoclonal antibody
(Transduction Laboratories, Lexington, Ky), anti-phos-
pho-p42/44 monoclonal antibody (Cell Signaling, Bev-
erly, Mass); anti-phospho-p38 monoclonal antibody (Sig-
ma, St Louis, Mo); and anti-phospho-JNK monoclonal
antibody, anti-ERK antibody, anti-JNK antibody, and anti-
p38 antibody (Santa Cruz Biotechnology Inc, Santa Cruz,
Calif) were used as the primary antibodies for detecting
bFGF, phosphorylated ERK1/2, phosphorylated JNK,
phosphorylated p38, total ERK, total JNK, and total p38,
respectively. Sheep anti-mouse imunoglobulin G horserad-
ish peroxidase–linked antibody (Amersham Life Science
Inc, Arlington Heights, Ill) was used as secondary anti-
body, and the membrane was developed by the ECL West-
ern blot detection system (Amersham Life Science). Den-
sitometry was performed on all Western blot bands. bFGF
data were normalized with data for the PBS group. Each
phospho-MAPK datum was divided by total MAPK data
and normalized with the data for the normal vein.
MAPK immunohistochemistry
The midsection of the vein grafts was also examined
with immunohistochemistry. Paraffin-embedded 6 mm
thick cross sections were deparaffinized in xylene and hy-
drated with graded ethanol baths. The slides were incu-
bated with SSC 1X buffer (Promega Corp, Madison, Wis)
at 37° C for 30 minutes. Antigen exposure was performed
with 0.2% hyaluronidase (Sigma) in PBS at 37° C for 30
minutes, and endogenous peroxidase was blocked with 3%
hydrogen peroxide for 10 minutes. Primary antibody to all
activated MAPKs (anti-phosphorylated ERK1/2, anti-
phosphorylated JNK1, and anti-phosphorylated p38) was
incubated at room temperature for 30 minutes in separate
serial sections. Nonspecific immunoglobulin G and elimi-
nation of the primary antibody were used as control. Bio-
tinylated goat anti-mouse secondary antibody was incu-
bated at room temperature for 20 minutes (BioGenex, San
Ramon, Calif), and detection of the reaction was performed
with horseradish peroxidase label and chromagen devel-
oper (BioGenex).
Statistical analysis
Data were calculated for each group as mean  SEM
and were compared with analysis of variance with Fisher’s
protected least significant difference method of post hoc
testing. The data were computed with StatView 5.0.1
software (SAS Institute Inc, Cary, NC). P  .05 was
considered significant.
RESULTS
Microsurgery
Animal survival and graft patency rates were 100%. The
rabbits appeared healthy. There were no structural anoma-
lies of the carotid artery or external jugular vein.
Evaluation of gene transfer
-Galactosidase activity, an index of successful Ad.lacZ
infection, was documented with X-gal chromagen in day 4
AVG specimens. Sixty-five percent of AVG intima and
media cells stained positive for -galactosidase. Positive
X-gal chromagen reaction was detected in the cells of the
media and deeply into the adventitia in some sites. This
observation demonstrates the depth of AVG wall penetra-
tion achieved with adenovirally mediated gene transfer. No
detectable endogenous -galactosidase activity was noted
in PBS-treated or Ad.ASbFGF-treated grafts after process-
ing in X-gal chromagen, as previously demonstrated.20
Gene expression of ASbFGF RNA was confirmed with
RT-PCR. We previously demonstrated in this animal
model that only Ad.ASbFGF-treated grafts, and not
Ad.lacZ-treated and PBS-treated vein grafts, demonstrated
Ad.ASbFGF RNA expression.20
Western blot analysis for bFGF
bFGF content at days 7 and 21 in AVGs was deter-
mined with Western blot analysis. Both PBS and Ad.lacZ
samples contained equivalent amounts of bFGF, whereas
Ad.ASbFGF samples contained 40% less immunoreactive
bFGF by day 7 (P .01). At 21 days, the bFGF level in the
Ad.ASbFGF group was still significantly lower than in the
other groups, although the difference decrease was only
10% (Fig 1).
Fig 1. Densitometry of bFGF immunoreactivity in vein grafts at 7
and 21 days. All data were normalized with the data of the PBS
group. *P .01 versus PBS or Ad.LacZ at 7 days. #P .01 versus
PBS or Ad.LacZ at 21 days.
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Histologic analysis
Thirty minutes after implantation, grafts retained an
endothelial monolayer and had no neointimal thickening.
There were no differences between grafts in the PBS and
Ad.ASbFGF groups (Fig 2, A and B). At 7 days, there were
fibroblasts and inflammatory cells in the adventitia and
several layers of neointimal cells (Fig 2, C and D), but no
differences were noted in neointimal thickness between
groups (PBS, 11.7  1.3 m; Ad.lacZ, 12.9  1.3 m;
Ad.ASbFGF, 9.1 1.0 m) (Fig 3). By 21 days, however,
there was a well-formed neointima in the PBS group
(60.2  2.1 m) and the Ad.lacZ group (57.2  1.7
m)(Fig 2, E; Fig 3), whereas the neointimal thickness in
the Ad.ASbFGF group (39.4  2.1 mm) was markedly
reduced (34%; P  .01)(Fig 2, F; Fig 3).
MAPK activation in vein grafts
ERK activation. To determine the activity of MAPK
after graft implantation, we measured the phosphorylation
of ERK1/2 with the use of an anti-active p42/p44 MAPK
antibody. ERK1 activation was detected by 30 minutes,
with peak activation from 4 to 7 days and activity decreasing
thereafter (Fig 4, A). Densitometric analysis showed that
peak activation of ERK1 was 1.96-fold greater in AVGs
Fig 2. Representive cross sections of AVGs. A, PBS at 30 minutes. B, Ad.ASbFGF at 30 minutes. C, PBS at 7 days.
D, Ad.ASbFGF at 7 days. E, PBS at 21 days. F, Ad.ASbFGF at 21 days. Neointima is represented between arrowheads.
(Original magnification,  200).
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than in normal vein. Activation of ERK2 showed the same
pattern as for ERK1 (data not shown). The kinetics of
ERK1 activation in grafts treated with Ad.ASbFGF were
similar but of less magnitude at all time points (Fig 4, A).
JNK and p38 activation. The trend in both JNK and
p38 activation was similar to that for ERK1/2. JNK and
p38 activation in the PBS group doubled by 4 days after
implantation (P  .01) and decreased thereafter (Fig 4, B
and C). Also similar to ERK1/2, activation of JNK and p38
was attenuated in grafts treated with Ad.ASbFGF (Fig 4, B
and C).
Immunohistochemistry
ERK1/2-activated cells were increased in both the
neointima and adventitia by 7 days in control vein grafts
(Fig 5). By 21 days, ERK-activated cells remained in the
neointima and adventitia. Control sections showed no
staining (data not shown). Staining for JNK and p38 acti-
vation also demonstrated a similar pattern (data not
shown). Vein grafts treated with AdASbFGF demonstrated
a similar pattern of MAPK staining for ERK1/2, JNK, and
p38 as for the control vein grafts (data not shown).
DISCUSSION
Intimal thickness at 21 days in the rabbit carotid artery
vein graft model was reduced by 34% with Ad.ASbFGF
(Figs 2 and 3). In addition, MAPK is activated in vein grafts
after implantation, and MAPK activation is inhibited 20%
to 35% by ASbFGF (Fig 4).
Vein grafts implanted in the arterial circulation develop
wall thickening, with smooth muscle cell hyperplasia and
deposition of extracellular matrix in the intima and media,
an adaptive process that has been referred to as arterializa-
tion. In about 20% of implanted vein grafts, however,
excessive NIH develops, with clinically significant steno-
sis.4-6 We previously reported positive remodeling in this
vein graft model, at a later time point, ie, 2 months.20 This
study extends that work, demonstrating reduced neointi-
mal thickening at 3 weeks in grafts treated with AdASbFGF
(Fig 3). The strong response in the neointima and not the
adventitia to the antisense transgene may reflect its intralu-
minal delivery and thus presumed higher levels of exposure
in the intima and media. Hemodynamic forces are impor-
tant in regulation of both the structure and function of the
blood vessel wall.25-26 In particular, the effects of shear
stress on endothelial cells have been studied in vitro.27-28
Several genes have been identified from both in vitro effects
of shear on endothelial cells and in vivo AVGs, such as
platelet-derived growth factor, bFGF, interleukin-1, vascu-
lar endothelial growth factor, transforming growth fac-
tor–, and tumor necrosis factor–.8,9,16,27,29-33 bFGF has
been implicated as a local mitogen active in this process.
This heparin-binding polypeptide is present in the nucleus
and cytoplasm of smooth muscle and endothelial cells and
in the extracellular matrix.11,13 bFGF is released from cells
at injury,12 and on release it binds to specific bFGF recep-
tors, triggering a cascade of signal transduction that in-
cludes the ras-MAPK pathway.34-37
Inhibition of bFGF synthesis with an antisense oligo-
nucleotide substantially decreases NIH in AVGs at 21 days.
We opted to use an adenoviral vector because of its high
transfection efficiency and safety.14,24,38,39 Although ad-
enoviral vector transfection efficiency is higher than with
liposomal or retroviral vectors, the toxicity of adenoviral
vectors at a dose of 1  1010 plaque-forming units per
milliliter is minimal in rabbit balloon injury or rabbit vein
graft models.18,20 In the rabbit vein graft model, the trans-
gene is present for 10 to 14 days,20 and NIH is completed
by 3 weeks; therefore the adenovirus vector maximum
expression coincides with the period in which NIH is
developing. Our Western blot analysis results demonstrate
that Ad.ASbFGF inhibits bFGF protein synthesis by 40% at
7 days, and this decrease in bFGF protein synthesis may
have a role in reducing NIH at 21 days. These results
suggest that bFGF participates in development of both
NIH and arterialization of vein grafts.
Activation of MAPK cascades is a major pathway for the
regulation of proliferation and migration in many cell
types.40,41 Mechanical stress and growth factors activate
MAPKs in vascular endothelial and smooth muscle
cells.28,42 An advantage of the AVG model is the clear
transition from low shear stress to high shear stress condi-
tions with implantation. Our group previously reported
that MAPKs are differently activated by shear stress and
cyclic strain in vitro.28 In this vein graft model, however, all
three MAPKs demonstrated a similar pattern of activation,
with activation demonstrated within 30 minutes (Fig 4).
This may reflect a difference in activity in vivo compared
with responses previously demonstrated in vitro.28 All
MAPKs also demonstrated peak activation by 4 or 7 days,
decreasing by 21 days. This period of activation coincides
with the development of NIH, usually complete by 3 weeks
in rabbit vein grafts.1,14-17 Grafts treated with ASbFGF
demonstrated reduced NIH (Fig 3) and blunted MAPK
Fig 3. Neointimal thickness in AVGs at 7 and 21 days. Intimal
thickness was measured in hematoxylin-eosin stained tissue section
with computerized digital morphometry. Results are mean of four
experiments. *P  .01 versus PBS or Ad.LacZ group.
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activation (Fig 4) at a time corresponding to development
of NIH. These results support the hypothesis that MAPK
signal cascades may have a role in the development of
neointimal hyperplasia in AVGs. Although all three MAPKs
demonstrated similar patterns of activation and different
MAPKs may affect different downstream cellular functions,
the complex process of vein graft adaptation and remodel-
ing likely requires multiple cellular functions that are stim-
ulated by several intracellular signal transduction pathways.
Thus it is likely that additional pathways may be involved.
Immunohistochemistry demonstrated that almost all
neointimal cells were positive for phospho-MAPK at 7
days, supporting a role for MAPK activation in the remod-
eling response. Although clear differences between PBS
and Ad.ASbFGF groups were not clearly demonstrated,
this may reflect reduced sensitivity of this technique. In
addition, because we used the mid-portion of the graft, this
could reflect sampling error, since NIH is more profound at
the anastomotic ends. Many adventitial inflammatory cells
and fibroblasts were MAPK-positive and medial smooth
muscle cells were MAPK-negative at early time points.
Some groups suggest that adventitial myofibroblasts mi-
grate to the intima to form NIH.43-46 Our results may be
consistent with this theory. Of interest, we also observed
reduced adventitial MAPK stain in the areas of NIH (Fig
5). Inasmuch as we did not detect any gross differences in
perigraft inflammatory response between control and
Ad.ASbFGF groups, we did not stain the grafts for inflam-
Fig 4. Time course of MAPK activation in vein grafts treated with PBS and Ad.ASbFGF (n 	 4). Phospho-MAPK
densitometry data are normalized to total MAPK and to baseline activity in normal vein. In all three MAPK groups,
differences between PBS and Ad.ASBFGF groups are significant at both day 4 (P .01) and day 7 (P  .05).
Representative Western blot data demonstrating time course of activated MAPKs are given adjacent to each graph.
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matory cells; however, invading host inflammatory cells
may be a source of some relevant mediators.
In conclusion, our findings suggest that MAPKs have a
role in vein graft adaptation to the arterial circulation and
that reduced MAPK activation correlates with reduced
NIH. It is tempting to speculate that local treatment with
Ad.ASbFGF may alter the kinetics of MAPK activation,
enabling vein graft adaptation to the arterial circulation
without excessive NIH. Further studies will be needed for
confirmation.
This study was supported in part by grants from the
National Institutes of Health (NIH RO1 HL47345) and
Veterans Administration Merit Review (B.E.S.) and by an
American Heart Association Grant-In-Aid (A.K.H.).
REFERENCES
1. Zwolak RM, Adams MC, Clowes AW. Kinetics of vein graft hyperplasia:
Association with tangential stress. J Vasc Surg 1987;5:126-36.
2. Szilagyi DE, Elliot J, Hageman J, Smith R, Dall’Olmo C. Biologic fate
of autogenous vein implants as arterial substitutes: Clinical, angio-
graphic and histopathologic observations in femoro-popliteal opera-
tions for atherosclerosis. Ann Surg 1973;178:232-46.
3. Nikkari ST, Clowes AW. Restenosis after vascular reconstruction. Ann
Med 1994;26:95-100.
4. Mills JL, Fujitani RM, Taylor SM. The characteristics and anatomic
distribution of lesions that cause reversed vein graft failure: A five-year
prospective study. J Vasc Surg 1993;17:195-204.
5. Fitzgibbon GM, Kafka HP, Leach AJ, Koen WJ, Hooper GD, Burton
JR. Coronary bypass graft fate and patient outcome: Angiographic
follow-up of 5,065 grafts related to survival and reoperation in 1,388
patients during 25 years. J Am Coll Cardiol 1996;28:616-26.
6. Caps MT, Cantwell-Gab K, Bergelin RO, Strandness DE Jr. Vein graft
lesions: Time of onset and rate of progression. J Vasc Surg 1995;22:
466-74.
7. Bourassa MG. Long-term vein graft patency. Curr Opin Cardiol 1994;
9:685-91.
8. Sterpetti A, Cucina A, Lepidi S, Randone B, Stipa F, Aromatario C, et al.
Progression and regression of myointimal hyperplasia in experimental
vein grafts depends on platelet-derived growth factor and basic fibro-
blastic growth factor production. J Vasc Surg 1996;23:568-75.
9. Sterpetti AV, Cucina A, Lepidi S, Randone B, Corvino V, D’Angelo LS,
et al. Formation of myointimal hyperplasia and cytokine production in
experimental vein grafts. Surgery 1998;123:461-9.
10. Rifkin DB, Moscatelli D. Recent developments in the cell biology of
basic fibroblast growth factor. J Cell Biol 1989;109:1-6.
11. Rifkin DB, Quarto N, Mignatti P, Bizik J, Moscatelli D. New observa-
tions on the intracellular location and release of bFGF. Ann NY Acad Sci
1991;638:204-6.
12. Gajdusek CM, Carbon S. Injury-induced release of basic fibroblast
growth factor from bovine aortic endothelium. J Cell Physiol 1989;
139:570-9.
13. Yu ZX, Biro S, Fu YM, Sanchez J, Smale G, Sasse J, et al. Localization
of basic fibroblast growth factor in bovine endothelial cells: Immuno-
histochemical and biochemical studies. Exp Cell Res 1993;204:247-59.
14. Stark VK, Warner TF, Hoch JR. An ultrastructural study of progressive
intimal hyperplasia in rat vein grafts. J Vasc Surg 1997;26:94-103.
15. Kohler TR, Kirkman TR, Gordon D, Clowes AW. Mechanism of
long-term degeneration of arterialized vein grafts. Am J Surg 1990;160:
257-61.
16. Hoch JR, Stark VK, Hullett DA, Turnipseed WD. Vein graft intimal
hyperplasia: Leukocytes and cytokine gene expression. Surgery 1994;
116:463-71.
17. Davies MG, Hagen PO. Pathobiology of intimal hyperplasia. Br J Surg
1994;81:1254-69.
18. Hanna AK, Fox JC, Neschis DG, Safford SD, Swain JL, Golden MA.
Antisense basic fibroblast growth factor gene transfer reduces neointi-
mal thickening after arterial injury. J Vasc Surg 1997;25:320-5.
19. Cano E, Mahadevan LC. Parallel signal processing among mammalian
MAPKs. Trends Biochem Sci 1995;20:117-22.
20. Hanna AK, Duran WN, Leconte I, Fox JC, Neschis DG, Hobson RW
II, et al. Adenoviral-mediated expression of antisense RNA to basic
fibroblast growth factor reduces tangential stress in arterialized vein
grafts. J Vasc Surg 2000;31:770-80.
21. Fox JC, Shanley JR. Antisense inhibition of basic fibroblast growth
factor induces apoptosis in vascular smooth muscle cells. J Biol Chem
1996;24;12578-84.
22. Leconte I, Fox JC, Baldwin HS, Buck CA, Swain JL. Adenoviral-
mediated expression of an antisense RNA to fibroblast growth factors
disrupts murine vascular development. Dev Dyn 1998;213:421-30.
23. Yang Y, Raper S, Cohn J, Englehardt J, Wilson J. An approach for
treating the hepatobiliary disease of cystic fibrosis by somatic gene
transfer. Proc Natl Acad Sci USA 1993;90:4601-5.
24. Berkner K. Development of adenovirus vectors for the expression of
heterologous genes. Biotechniques 1988;6:616-29.
25. Traub O, Berk BC. Laminar shear stress: Mechanisms by which endo-
thelial cells transduce an atheroprotective force. Arterioscler Thromb
Vasc Biol 1998;18:677-85.
26. Lehoux S, Tedgui A. Signal transduction of mechanical stresses in the
vascular wall. Hypertension 1998;32:338-45.
27. Rensik N, Gimbrone MA. Hemodynamic forces are complex regulators
of endothelial gene expression. FASEB J 1995;9:874-82.
28. Azuma N, Duzgun A, Ikeda M, Kito H, Akasaka N, Sasajima T, et al.
Endothelial cell response to different mechanical force. J Vasc Surg
2000;32:789-94.
Fig 5. Representive cross sections of AVGs stained for phosphorylated ERK. A, PBS at 7 days. B, PBS at 21 days.
Neointima is represented between white arrowheads. Phospho-ERK– positive cells are represented with black arrows.
(Original magnification,  200).
JOURNAL OF VASCULAR SURGERY
April 2003872 Yamashita et al
29. Faries PL, Marin ML, Veith FJ, Ramirez JA, Suggs WD, Parsons RE, et
al. Immunolocalization and temporal distribution of cytokine expres-
sion during the development of vein graft intimal hyperplasia in an
experimental model. J Vasc Surg 1996;24:463-71.
30. Mtsumata M, Fishel RS, Nerem RM, Alexander RW, Berk BC. Fluid
shear stress stimulates platelet-derived growth factor expression in
endothelial cells. Am J Physiol 1993;265:H3-8.
31. Hsieh HJ, Li NQ, Frangos JA. Shear stress increases endothelial plate-
let-derived growth factor mRNA levels. Am J Physiol 1991;260:
H642-6.
32. Malek AM, Gibbons GH, Dzau VJ, Izumo S. Fluid shear stress differ-
entially modulates expression of genes encoding basic fibroblast growth
factor and platelet-derived growth factor B chain in vascular endothe-
lium. J Clin Invest 1993;92:2013-21.
33. Zheng W, Seftor EA, Meininger CJ, Hendrix MJ, Tomanek RJ. Mech-
anisms of coronary angiogenesis in response to stretch: Role of VEGF
and TGF-beta. Am J Physiol 2001;280:H909-17.
34. Nakamura T, Mochizuki Y, Kanetake H, Kanda S. Signals via FGF
receptor 2 regulate migration of endothelial cells. Biochem Biophys Res
Commun 2001;289:801-6.
35. Pintucci G, Moscatelli D, Saponara F, Biernacki PR, Baumann FG,
Bizekis C, et al. Lack of ERK activation and cell migration in FGF-2-
deficient endothelial cells. FASEB J 2002;16:598-600.
36. Giuliani R, Bastaki M, Coltrini D, Presta M. Role of endothelial cell
extracellular signal-regulated kinase1/2 in urokinase-type plasminogen
activator upregulation and in vitro angiogenesis by fibroblast growth
factor-2. J Cell Sci 1999;112 (Pt 15):2597-606.
37. Jaye M, Schlessinger J, Dionne CA. Fibroblast growth factor receptor
tyrosine kinases: molecular analysis and signal transduction. Biochim
Biophys Acta. 1992;1135:185-99.
38. Baek S, March KL. Gene therapy for restenosis: Getting nearer the heart
of the matter. Circ Res 1998;82:295-305.
39. Gao G, Yiping Y, Wilson JM. Biology of adenovirous vectors with E1
and E4 deletions for liver-directed gene therapy. J Virol 1996;70:8934-
43.
40. Davis RJ. The mitogen-activated protein kinase signal transduction
pathway. J Biol Chem 1993;268:14553-6.
41. Seger R, Krebs EG. The MAPK signaling cascade. FASEB J 1995;9:
726-35.
42. Li C, Xu Q. Mechanical stress-initiated signal transductions in vascular
smooth muscle cells. Cell Signal 2000;12:435-45.
43. Zalewski A, Shi Y. Vascular myofibroblasts: Lessons from coronary
repair and remodeling. Arterioscler Thromb Vasc Biol 1997;17:417-
22.
44. Shi Y, O’Brien JE, Frad A, Mannion JD, Wang D, Zalewski A. Adven-
titial myofibroblasts contribute to neointimal formation in injured
porcine coronary arteries. Circulation 1996;94:1655-64.
45. Miller FJ Jr. Adventitial fibroblasts: Backstage journeymen. Arterioscler
Thromb Vasc Biol 2001;21:722-3.
46. Li G, Chen SJ, Oparil S, Chen YF, Thompson JA. Direct in vivo
evidence demonstrating neointimal migration of adventitial fibroblasts
after balloon injury of rat carotid arteries. Circulation
2000;101:1362-5.
Submitted May 21, 2002; accepted Sep 16, 2002.
Receive table of contents by e-mail
To receive the tables of contents by e-mail, sign up through our Web site at
http://www.mosby.com/jvs
Choose E-mail Notification
Simply type your e-mail address in the box and click the Subscribe button
Alternatively, you may send an e-mail message to majordomo@mosby.com
Leave the subject line blank and type the following as the body of your message:
subscribe jvs_toc
You will receive an e-mail to confirm that you have been added to the mailing list.
Note that TOC e-mails will be sent out when a new issue is posted to the Web site.
JOURNAL OF VASCULAR SURGERY
Volume 37, Number 4 Yamashita et al 873
